Open Access
EDITORIAL
Daniel Serin
Oncologie, Vol.24, No.1, pp. 1-2, 2022, DOI:10.32604/oncologie.2022.020553
Abstract This article has no abstract. More >
Open Access
REVIEW IN FRENCH
Elsa Maitre, Xavier Troussard*
Oncologie, Vol.24, No.1, pp. 3-24, 2022, DOI:10.32604/oncologie.2022.021490
Abstract Hairy cell leukemia (LT) accounts for 2% of all leukemias. The diagnosis is based on the presence in the blood and/
or the marrow of hairy cells expressing CD103, CD123, CD11c and CD25. The BRAFV600E mutation, a molecular
marker of the disease, is present in more than 80% of cases. LT should be distinguished from other chronic B-cell
lymphoproliferative disorders, including the variant form of hairy cell leukemia (HCL-V) and diffuse splenic red
pulp lymphoma (DSRPL). Progress has recently been made in the management of patients. The purine analogues
(PNAs) in monotherapy, deoxycoformycin (DCF) or 2-chloro-deoxyadenosine (CDA), remain the first-line… More >
Open Access
VIEW POINT IN FRENCH
Jean-Claude Ferrandez1,*, Pierre-Henri Ganchou2, Serge Theys3, Maria Torres-Lacomba4, Daniel Serin1
Oncologie, Vol.24, No.1, pp. 25-33, 2022, DOI:10.32604/oncologie.2022.018110
Abstract Upper limb lympedema is a frequent consequence of breast cancer treatment. The International Society of Lymphology recommends physical therapy for lymphedema management. This treatment includes a combination of
manual lymphatic drainage and high-compression bandaging. Actually, the effectiveness of manual lymphatic
drainage remains an area of controversy, especially because of the many different techniques called “manual lymphatic drainage” since 1930. The purpose of this review was to emphasise the efficacy of these different techniques according to physiological data and evidence-based practice. To improve the manual lymphatic drainage
efficiency, the pressure, sometimes important, should be tailored to each edema and the techniques… More >
Open Access
REVIEW
Federico Cappellacci*, Gian Luigi Canu, Stefano Piras, Giacomo Anedda, Pietro Giorgio Calò, Fabio Medas
Oncologie, Vol.24, No.1, pp. 35-50, 2022, DOI:10.32604/oncologie.2022.020864
Abstract Thyroid cancer is the fifth most common cancer in the USA, with differentiated subtype accounting for more
than 95% of neoplasm. Surgery remains the mainstay of treatment, either with lobectomy or total thyroidectomy.
In the last decades, many technological innovations have been introduced in this field. The aim of this review is to
illustrate the most recent advances regarding the classical surgical approach, particularly regarding hemostatic
devices, parathyroid identification with fluorescence systems, intraoperative identification of lymph node metastases, and intraoperative neuromonitoring. More >
Open Access
REVIEW
Hiba Alzoubi1, Alameen Alsabbah2, Rosario Caltabiano3, Giuseppe Broggi3,*
Oncologie, Vol.24, No.1, pp. 51-63, 2022, DOI:10.32604/oncologie.2022.020890
Abstract The 2021 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS)
improved our understanding of the brain neoplasm biology. In more details, differences between diffuse gliomas
that primarily occur in adults and those that primarily occur in children have been identified by the terms “adult-type” and “pediatric-type” diffuse gliomas. More importantly, both diagnostic and grading criteria for adult-type
diffuse astrocytomas have been modified, by adopting novel molecular markers: diffuse astrocytomas, IDH-mutant have been grouped into a single entity and graded as CNS WHO grades 2, 3, or 4, with the assignment
of Grade 4 in the… More >
Open Access
REVIEW
Hangxing Wang1,#, Jingyun Fang1,#, Yujiao Wang2,#, Shuo Li2, Zirui Wang2, Wei He2, Nan Wang1, Shuang Luo1, Huimei Zou3,*, Fan Zhang4,5,*
Oncologie, Vol.24, No.1, pp. 65-83, 2022, DOI:10.32604/oncologie.2022.021863
Abstract Lung cancer is the most common malignant tumor with the highest morbidity and mortality in the world, and non-small cell lung cancer (NSCLC) accounts for the vast majority of cases. At present, its main treatment methods are still traditional surgery, radiotherapy and chemotherapy, with disadvantages such as a high recurrence rate and limited effectiveness. Therefore, a new, better treatment method is urgently needed. Gene editing technology, as a new genetic engineering approach, has shown great potential in gene research, gene therapy and genetic improvement. It has also emerged as a promising treatment for lung cancer. This paper reviews the current… More >
Open Access
REVIEW
Hao Luo1,#,*, Yanjie Ji2,#, Xinrong Gao1, Xinying Liu1, Yunzhao Wu3, Yingli Wu3,*
Oncologie, Vol.24, No.1, pp. 85-99, 2022, DOI:10.32604/oncologie.2022.021705
Abstract The ubiquitin-proteasome system (UPS) is an important pathway for cellular protein degradation. The components of this pathway, including the proteasome, ubiquitinase, and deubiquitinase, are highly specialized and
strictly regulated. The ubiquitin-specific protease 2 (USP2) belongs to the ubiquitin-specific proteases, a subgroup
of deubiquitinating enzymes. USP2 plays essential roles in regulating cell survival, cell cycle, circadian rhythm, cell
metabolism, inflammatory response, antiviral response, and metastasis by interacting with certain proteins such
as Cyclin D1, PER1, CRY1, HDM2/p53, FASN, LDLR, TRAF6, TBK1, and TGFBR1-TGFBR2 complex. Elevation
of USP2 has been observed in a variety of cancers, including glioma, testicular cancer, breast cancer,… More >
Open Access
ARTICLE
Dong Yan1,#, Chunxiao Li2,#, Yantong Zhou2, Xue Yan1, Weihua Zhi1, Haili Qian2,*, Yue Han1,*
Oncologie, Vol.24, No.1, pp. 101-111, 2022, DOI:10.32604/oncologie.2022.020357
Abstract Hepatocellular carcinoma (HCC) is one of the most deadly types of cancer. Sorafenib is currently the only available first-line molecular targeted drug approved by the FDA for HCC. However, primary and secondary resistance
is often encountered with treatment with sorafenib. Genomic alterations found in HCC represent potential targets
to develop new drugs or new combinational strategies against this type of cancer. Here we analyzed genomic
alterations from the TCGA database of HCC samples and the corresponding targeted drugs available to the clinic
to identify candidate drugs that might hold promise when used in combination with sorafenib. Our results
revealed that… More >
Open Access
ARTICLE
Beifen Dai1,#, Zhihao Xu2,#, Hongjue Li3, Bo Wang3, Jinsong Cai1, Xiaomo Liu4,*
Oncologie, Vol.24, No.1, pp. 113-130, 2022, DOI:10.32604/oncologie.2022.020259
Abstract Large-scale genomic studies are important ways to comprehensively decode the human genomics, and provide
valuable insights to human disease causalities and phenotype developments. Genomic studies are in need of high
throughput bioinformatics analyses to harness and integrate such big data. It is in this overarching context that
artificial intelligence (AI) offers enormous potentials to advance genomic studies. However, racial bias is always an
important issue in the data. It is usually due to the accumulation process of the dataset that inevitability involved
diverse subjects with different races. How can race bias affect the outcomes of AI methods? In this work,… More >
Open Access
ARTICLE
Jiayi Huang1, Xue Bai1, Xiaofeng Xie1, Liping Chen1, Xiaofeng Lan1, Qiuyi Zhang1, Lin Song1, Pengjiao Hong2,3, Caiwen Du1,*
Oncologie, Vol.24, No.1, pp. 131-145, 2022, DOI:10.32604/oncologie.2022.019881
Abstract Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with
other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, in China.
The current study aimed to explore the efficacy and safety of oral vinorelbine in patients with metastatic breast
cancer in real-world clinical practice. Methods: A total of 194 patients with metastatic breast cancer received oral
vinorelbine as a treatment between February 2017 and January 2021 at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences… More >
Login
Register
Submit a Paper
Propose a Special lssue